Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Media / Science Center
  • Contact Us
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
    • Videos
  • Events & Presentations
    • Events
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
  • Videos
Apr 25, 2024 8:00am EDT

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Apr 19, 2024 8:00am EDT

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Apr 09, 2024 8:00am EDT

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Mar 15, 2024 8:00am EDT

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024 8:00am EST

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Feb 21, 2024 8:00am EST

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Feb 15, 2024 8:00am EST

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Feb 13, 2024 8:00am EST

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Feb 06, 2024 8:00am EST

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Jan 31, 2024 8:00am EST

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio